Shield Therapeutics PLC (LON:STX) said it is now well placed for substantial future growth after a “transformational” year.
The group said it is on track to launch its iron deficiency lead product Accrufer in the US by the end of June.
READ: Shield Therapeutics welcomes real-world data that points lead drug's potential in inflammatory bowel disease
Increasing sales in the US are estimated to turn the monthly cash flow positive between 15-18 months after launch, with potential for net sales to reach US$100mln in the third year after launch.
The treatment is also to launch in further markets in Europe towards the end of 2021 and early 2022, while Shield plans to outlicence it in markets outside the US, Europe, China and Australia/New Zealand.
As well as the US launch costs including sales representatives, market research and data analysis, marketing spend and other US operational costs, the pharma company will also start the main stage of the paediatric study in mid-2021, which should last for around two years and cost £4.5mln in total.
Royalty revenues from the Norgine licence agreement in Europe will also continue to grow steadily, Shield added.
In the year to end-December, revenue rocketed 93% to £10.4mln and total loss was cut by 70% to £2.6mln.
Net cash at period-end was £2.9mln but the balance sheet was bolstered by a £29.2mln fundraise in March.
Shares rose 6% to 48.25p on Thursday morning.